Published in Nat Rev Cardiol on October 11, 2011
Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents (ISAR-TEST6) | NCT01068106
BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. EBioMedicine (2015) 0.88
Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. PLoS One (2012) 0.82
TLR accessory molecule RP105 (CD180) is involved in post-interventional vascular remodeling and soluble RP105 modulates neointima formation. PLoS One (2013) 0.80
Computational Modeling of Inflammation and Wound Healing. Adv Wound Care (New Rochelle) (2013) 0.79
A Comparison of Fully-Coupled 3D In-Stent Restenosis Simulations to In-vivo Data. Front Physiol (2017) 0.78
Bioabsorbable stent quo vadis: a case for nano-theranostics. Theranostics (2014) 0.77
Secondary revascularization after CABG surgery. Nat Rev Cardiol (2012) 0.75
Amphiphilic macromolecule nanoassemblies suppress smooth muscle cell proliferation and platelet adhesion. Biomaterials (2016) 0.75
Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis. J Saudi Heart Assoc (2016) 0.75
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med (1979) 6.39
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 4.07
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 3.82
The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol (2011) 3.71
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet (2007) 3.20
Mechanisms of Taxol resistance related to microtubules. Oncogene (2003) 3.16
In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol (2010) 2.85
Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (2003) 2.81
Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc (2003) 2.71
Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation (1999) 2.67
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (2011) 2.54
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med (2001) 2.54
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation (2010) 2.54
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol (2003) 2.53
Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation (2009) 2.47
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet (2010) 2.38
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation (2001) 2.34
Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31
Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA (2006) 2.16
Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation (2009) 2.09
Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J (2009) 2.03
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA (2006) 2.03
Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation (1999) 1.94
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol (2010) 1.93
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J (2009) 1.81
Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv (2010) 1.81
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol (2007) 1.81
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol (2010) 1.80
Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv (2007) 1.77
Coronary stent restenosis in patients treated with cilostazol. Circulation (2005) 1.73
Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet (2002) 1.72
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol (2011) 1.69
Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J (2007) 1.69
Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv (2009) 1.67
Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation (2007) 1.64
Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol (2004) 1.61
Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart (2009) 1.55
A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv (2009) 1.50
Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J (2007) 1.49
Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol (2008) 1.47
Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. Int J Cardiol (2009) 1.46
Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol (2002) 1.46
Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. Circ J (2010) 1.42
Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis. Catheter Cardiovasc Interv (2010) 1.41
2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol (2010) 1.38
Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc Natl Acad Sci U S A (2005) 1.35
Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol (2011) 1.32
PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol (2001) 1.31
Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation (2004) 1.26
A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv (2010) 1.23
Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A (2010) 1.19
Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation (2007) 1.18
Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation (2002) 1.16
Coronary stents: looking forward. J Am Coll Cardiol (2010) 1.11
Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol (2007) 1.07
Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation (2004) 1.06
Peri-implant bone formation and implant integration strength of peptide-modified p(AAM-co-EG/AAC) interpenetrating polymer network-coated titanium implants. J Biomed Mater Res A (2007) 1.05
Fabrication of endothelial progenitor cell (EPC)-seeded intravascular stent devices and in vitro endothelialization on hybrid vascular tissue. Biomaterials (2003) 1.03
Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler Thromb Vasc Biol (2005) 1.02
Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol Ther (2008) 1.01
Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circ Cardiovasc Interv (2010) 0.99
Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention (2010) 0.99
Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. J Am Coll Cardiol (2007) 0.96
A pyrrole-imidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc Res (2008) 0.96
Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Am J Cardiol (2008) 0.96
Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv (2010) 0.95
Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol (1995) 0.94
Novel gene silencer pyrrole-imidazole polyamide targeting lectin-like oxidized low-density lipoprotein receptor-1 attenuates restenosis of the artery after injury. Hypertension (2008) 0.93
A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. EuroIntervention (2010) 0.92
Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv (2010) 0.91
Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc Interv (2006) 0.91
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol (2008) 0.91
Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine (2007) 0.90
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev (2011) 0.90
Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. Circulation (2010) 0.89
Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". J Am Coll Cardiol (2011) 0.89
Drug-eluting stent restenosis the pattern predicts the outcome. J Am Coll Cardiol (2006) 0.89
Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis. Biomed Eng Online (2010) 0.88
The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. EuroIntervention (2007) 0.87
Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol (2010) 0.87
Endothelial progenitor cell capture stent implantation in patients with ST-segment elevation acute myocardial infarction: one year follow-up. EuroIntervention (2010) 0.87
Cutting balloon coronary angioplasty--initial clinical experience. Clin Cardiol (1993) 0.86
Synthetic pyrrole-imidazole polyamide inhibits expression of the human transforming growth factor-beta1 gene. J Pharmacol Exp Ther (2005) 0.86
Treatment of drug-eluting stent restenosis. Am Heart J (2007) 0.86
The bioabsorption process: tissue and cellular mechanisms and outcomes. EuroIntervention (2009) 0.85
The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv (2008) 0.84
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol (2006) 2.00
Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo. Circ Res (2004) 1.93
Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation (2005) 1.78
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res (2007) 1.76
Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol (2009) 1.67
In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation (2002) 1.61
Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med (2009) 1.59
Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. EuroIntervention (2011) 1.54
Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries. Cardiovasc Res (2005) 1.52
Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res (2012) 1.49
Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J (2013) 1.48
Toll-like receptor 4 is involved in outward arterial remodeling. Circulation (2003) 1.43
Drug-eluting stents: results, promises and problems. Int J Cardiol (2005) 1.41
Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol (2011) 1.32
Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia. Arterioscler Thromb Vasc Biol (2007) 1.22
Epigenetics in atherosclerosis and inflammation. J Cell Mol Med (2010) 1.21
Arteriovenous access failure: more than just intimal hyperplasia? Nephrol Dial Transplant (2013) 1.18
Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation (2007) 1.18
Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J (2005) 1.16
Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. Eur Heart J (2009) 1.14
Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood (2002) 1.13
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res (2005) 1.07
MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1(+)/Lin(-) progenitor cells in ischaemia. Cardiovasc Res (2011) 1.04
Gene transfer of tissue inhibitor of metalloproteinases-3 reverses the inhibitory effects of TNF-alpha on Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. J Immunol (2005) 1.04
SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am J Hypertens (2011) 1.03
Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. Biomaterials (2005) 1.01
Hypercholesterolemia reduces collateral artery growth more dominantly than hyperglycemia or insulin resistance in mice. Arterioscler Thromb Vasc Biol (2006) 1.01
TR3 orphan receptor is expressed in vascular endothelial cells and mediates cell cycle arrest. Arterioscler Thromb Vasc Biol (2003) 0.98
Insights into mechanisms behind arteriogenesis: what does the future hold? J Leukoc Biol (2008) 0.97
The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions. EMBO Mol Med (2011) 0.96
Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation. J Lipid Res (2013) 0.96
Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. J Vasc Surg (2009) 0.96
Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. J Clin Endocrinol Metab (2004) 0.96
Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ Res (2013) 0.95
Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. Arterioscler Thromb Vasc Biol (2011) 0.95
Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr Pharm Des (2011) 0.94
TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol (2006) 0.94
Systemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differently. Atherosclerosis (2010) 0.93
Lysine acetyltransferase PCAF is a key regulator of arteriogenesis. Arterioscler Thromb Vasc Biol (2013) 0.93
Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors. J Cell Mol Med (2012) 0.92
Nur77 modulates hepatic lipid metabolism through suppression of SREBP1c activity. Biochem Biophys Res Commun (2007) 0.90
Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol (2010) 0.90
Adenoviral activin a expression prevents intimal hyperplasia in human and murine blood vessels by maintaining the contractile smooth muscle cell phenotype. Circ Res (2002) 0.89
6-mercaptopurine inhibits atherosclerosis in apolipoprotein e*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler Thromb Vasc Biol (2010) 0.89
The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis (2006) 0.88
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention. J Am Coll Cardiol (2005) 0.87
A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. Hum Mol Genet (2011) 0.87
Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention. Expert Opin Ther Targets (2010) 0.86
Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 0.86
Inhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonists. Cardiovasc Res (2006) 0.86
Strain-dependent susceptibility for hypertension in mice resides in the natural killer gene complex. Am J Physiol Heart Circ Physiol (2010) 0.86
Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics (2012) 0.86
A small molecule approach to engineering vascularized tissue. Biomaterials (2013) 0.85
A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Cardiovasc Res (2010) 0.84
Short-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic mice. J Vasc Surg (2006) 0.83
Plaque rupture complications in murine atherosclerotic vein grafts can be prevented by TIMP-1 overexpression. PLoS One (2012) 0.83
VLDL receptor deficiency enhances intimal thickening after vascular injury but does not affect atherosclerotic lesion area. Atherosclerosis (2002) 0.83
Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration. Arterioscler Thromb Vasc Biol (2012) 0.82
Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis. Atherosclerosis (2013) 0.82
Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease. Biomark Med (2012) 0.82
Shear induced collateral artery growth modulated by endoglin but not by ALK1. J Cell Mol Med (2012) 0.81
Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality. Stroke Res Treat (2011) 0.81
Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA. Hum Gene Ther (2007) 0.80
Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia. Hum Gene Ther (2014) 0.80
TLR accessory molecule RP105 (CD180) is involved in post-interventional vascular remodeling and soluble RP105 modulates neointima formation. PLoS One (2013) 0.80
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thromb Haemost (2007) 0.80
Absence of chemokine (C-x-C motif) ligand 10 diminishes perfusion recovery after local arterial occlusion in mice. Arterioscler Thromb Vasc Biol (2014) 0.79
Pathway analysis using genome-wide association study data for coronary restenosis--a potential role for the PARVB gene. PLoS One (2013) 0.79
Complement factor C5a induces atherosclerotic plaque disruptions. J Cell Mol Med (2014) 0.79
Protease-activated receptor (PAR)2, but not PAR1, is involved in collateral formation and anti-inflammatory monocyte polarization in a mouse hind limb ischemia model. PLoS One (2013) 0.78
Inhibition of MicroRNA-494 Reduces Carotid Artery Atherosclerotic Lesion Development and Increases Plaque Stability. Ann Surg (2015) 0.77
Ingrowth of aorta vascular cells into basic fibroblast growth factor-impregnated vascular prosthesis material: a porcine and human in vitro study on blood vessel prosthesis healing. J Vasc Surg (2002) 0.76
Plaque angiogenesis and its relation to inflammation and atherosclerotic plaque destabilization. Curr Opin Lipidol (2016) 0.76
Drug-eluting stents studies in mice: do we need atherosclerosis to study restenosis? Vascul Pharmacol (2006) 0.76
C1-esterase inhibitor protects against early vein graft remodeling under arterial blood pressure. Atherosclerosis (2011) 0.75
Fibrinogen reduction and coagulation in cardiac surgery: an investigational study. Blood Coagul Fibrinolysis (2015) 0.75
Anti-apoptotic serpins as therapeutics in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets (2013) 0.75
Ingrowth of aorta wall into stent grafts impregnated with basic fibroblast growth factor: a porcine in vivo study of blood vessel prosthesis healing. J Vasc Surg (2004) 0.75
Future potential biomarkers for postinterventional restenosis and accelerated atherosclerosis. Biomark Med (2012) 0.75
Toll-like receptor 4 inhibitor TAK-242 treatment does not influence perfusion recovery in tissue ischemia. J Cardiovasc Pharmacol (2014) 0.75
von Willebrand factor deficiency leads to impaired blood flow recovery after ischaemia in mice. Thromb Haemost (2017) 0.75